PSMA-1007

Phase 3Small molecule

AABX advanced biochemical compounds GmbH

PSMA-1007 is one of 28 small molecule programs targeting Prostate Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Prostate CancerActive, not recruiting

Prostate CancerPhase 3

Active, not recruiting

Competition

Competitive Landscape

1399 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

Novantrone

Pfizer

Preclinical

5 2

PSMA-1007

AABX advanced biochemical compounds GmbH

Phase 3

2 3

Mekinist

Novartis

Preclinical

3 4

Trexall

Alnylam Pharmaceuticals

Preclinical

—5

Jatenzo

GGrupo Espanol de Tumores Neuroendocrinos

Preclinical

2 6

Viagra

VViatris Specialty LLC

Preclinical

1 7

Duragesic

CCephalon

Preclinical

1 8

Ranexa

MMenarini International Operations Luxembourg SA

Preclinical

1 9

Prednisone/prednisolone

Roche

Preclinical

3 10

Triptorelin Pamoate

Ipsen

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 3Recruiting

Prostate Cancer

NCT06122584

Clinical

Trials by Indication[1]

Prostate Cancer2 trials

Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer

Completed·AABX advanced biochemical compounds GmbH·Phase 3·NCT04742361·136 enrolled

Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed Prostate Cancer

Recruiting·AABX advanced biochemical compounds GmbH·Phase 3·NCT06122584·380 enrolled

Magnetic Resonance Imaging1 trial

Positron Emission Tomography / Magnetic Resonance Imaging (PET/MRI) Guided Biopsy in Men With Elevated PSA

Completed·IIrene Burger·N/A·NCT03187990·52 enrolled

Prostatectomy1 trial

Multi-modality Imaging (PCa) Using Sodium MRI and PSMA PET in Men Pre-prostatectomy

Active, not recruiting·GGlenn Bauman·Phase 2·NCT04053842·45 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for PSMA-1007. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PSMA-1007 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PSMA-1007. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — ABX advanced biochemical compounds GmbH company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AABX advanced biochemical compounds GmbH

PSMA-1007

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Trials by Indication[1]

Prostate Cancer2 trials

Magnetic Resonance Imaging1 trial

Prostatectomy1 trial

References

Drug Info

Quick Facts

Related News